Pier Capital Lowered Take (TTWO) Holding By $3.12 Million; Shorts at Cascadian Therapeutics (CASC) Raised By 12.18%

December 7, 2017 - By Adrian Erickson

Pier Capital Llc decreased Take (TTWO) stake by 30.28% reported in 2017Q2 SEC filing. Pier Capital Llc sold 42,780 shares as Take (TTWO)’s stock rose 13.22%. The Pier Capital Llc holds 98,487 shares with $7.23 million value, down from 141,267 last quarter. Take now has $11.96B valuation. The stock increased 0.67% or $0.7 during the last trading session, reaching $104.89. About 1.94M shares traded. Take-Two Interactive Software, Inc. (NASDAQ:TTWO) has risen 81.23% since December 7, 2016 and is uptrending. It has outperformed by 64.53% the S&P500.




Cascadian Therapeutics Incorporated (NASDAQ:CASC) had an increase of 12.18% in short interest. CASC’s SI was 1.68M shares in December as released by FINRA. Its up 12.18% from 1.49M shares previously. With 274,000 avg volume, 6 days are for Cascadian Therapeutics Incorporated (NASDAQ:CASC)’s short sellers to cover CASC’s short positions. The SI to Cascadian Therapeutics Incorporated’s float is 5.29%. The stock decreased 3.21% or $0.13 during the last trading session, reaching $3.92. About 544,981 shares traded or 53.75% up from the average. Cascadian Therapeutics, Inc. (NASDAQ:CASC) has declined 30.85% since December 7, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.

Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company has market cap of $198.20 million. The firm lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It currently has negative earnings. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.

Among 19 analysts covering Take-Two Interactive Software (NASDAQ:TTWO), 15 have Buy rating, 1 Sell and 3 Hold. Therefore 79% are positive. Take-Two Interactive Software had 67 analyst reports since July 28, 2015 according to SRatingsIntel. BMO Capital Markets initiated Take-Two Interactive Software, Inc. (NASDAQ:TTWO) on Wednesday, April 27 with “Outperform” rating. The firm has “Market Perform” rating by Cowen & Co given on Monday, October 9. The rating was maintained by Stifel Nicolaus on Monday, July 10 with “Buy”. Robert W. Baird maintained the stock with “Hold” rating in Thursday, September 14 report. The rating was maintained by BMO Capital Markets with “Buy” on Thursday, August 3. The stock of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) earned “Overweight” rating by KeyBanc Capital Markets on Wednesday, November 8. The rating was maintained by BMO Capital Markets on Monday, November 13 with “Outperform”. The firm has “Neutral” rating given on Thursday, February 4 by Wedbush. On Thursday, September 3 the stock rating was upgraded by BTIG Research to “Buy”. The rating was maintained by Oppenheimer with “Buy” on Thursday, August 3.

Analysts await Take-Two Interactive Software, Inc. (NASDAQ:TTWO) to report earnings on February, 6. They expect $0.84 EPS, up 18.31% or $0.13 from last year’s $0.71 per share. TTWO’s profit will be $95.80M for 31.22 P/E if the $0.84 EPS becomes a reality. After $0.76 actual EPS reported by Take-Two Interactive Software, Inc. for the previous quarter, Wall Street now forecasts 10.53% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: